PCSK9-targeted therapies: present and future approaches
- PMID: 34663945
- DOI: 10.1038/s41569-021-00634-0
PCSK9-targeted therapies: present and future approaches
References
-
- Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006). - DOI
-
- Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017). - DOI
-
- Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097–2107 (2018). - DOI
-
- Ridker, P. M. et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med. 376, 1527–1539 (2017). - DOI
-
- Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 382, 1507–1519 (2020). - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous